About this trial
Patients undergoing spine surgery frequently experience significant pain after surgery. This can limit patient activity and hinder rehabilitation. If inadequately treated, severe pain can result in emotional and psychological distress and ultimately impact long-term function, and increase the risk of developing pain that lasts longer than six months associated with depression, anxiety and disability.
More specifically, Erector Spinae Plane (ESP) block is a recently described plane block designed to block the dorsal and ventral rami of the thoracic spinal nerves. It has shown to be an effective modality for postoperative pain management as a part of multimodal analgesia in spinal surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
In patients who are allergic to local anesthetics.
ASA IV patients
Lack of informed consent
Pregnant patient.
Trial design
Parallel
Treatments tested in this trial
Erector Spinae (ESP) Block with Lidocaine/Bupivacaine
DrugBilateral ESP block at T1 level with 20 ml of 1:1 mixture (2% Lidocaine: 0.5% bupivacaine)
Erector Spinae (ESP) Block with placebo
DrugBilateral ESP block at T1 level with 20 ml of 0.9% normal saline
Treatment groups
Trial outcomes
Primary outcomes
Quality of Recovery 40 Questionnaire
the global Quality of Recovery-40 aggregate score is a scale from (1 to 5, where: 1 = very poor and 5 = excellent)
Secondary outcomes
Postoperative pain
is a visual analog scale from (1 to 10, where: 1 is the mildest and 10 the worst possible)
Opioids consumption
Patient Opioid/Non-Opioid Pain Medications Diary Card After Surgery
Sponsors and contacts
Click on the lead sponsor to view all of their trials.